About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Omega-3 Fatty Acids Efficacy in First-episode of Schizophrenia

NCT02210962·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Medical University of Lodz

Age

16–35

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Patients diagnosed with schizophrenia using Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) criteria
Patients aged between 16-35 years
Signed informed consent (parallel parents consent for individuals under 18 years of age)

You may not be if

Patients taking fish oil supplements (a washout period of 6 months is required)
Patients diagnosed with epilepsy or suffering from epileptic seizures
Patients receiving anticoagulant medication e.g., Warfarin
Patients receiving psychotherapy
Chronic somatic diseases
Psychoactive substance dependence
Pregnancy and lactation
Mental retardation or diagnosed organic brain injury

The record

StatusUnknown

PhasePhase 4

Taking part80

StartedSep 2011

UpdatedFeb 18, 2015

Conditions

Where1

Department of Affective and Psychotic Disorders Medical University of Lodz
Lodz, Łódź Voivodeship, Poland

Clareo Health | Omega-3 Fatty Acids Efficacy in First-episode of Schizophrenia